The international surgical journal with global reach

Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382: 1994-2004.

Published: 22nd July 2020

Authors: Bonaca MP, Bauersachs RM, Anand S, Debus ES, Nehler MR, Patel MR et al.

Conclusion

This study included 6564 patients randomly allocated aspirin alone, or aspirin plus rivaroxaban 2.5mg b.d. The composite outcome of adverse cardiovascular events at three years was reduced by the addition of rivaroxaban (17.3 versus 19.9 per cent, P=0.009), without increasing the risk of major bleeding.

Pubmed Link